Condition (MeSH)
Polycythemia
ClinicalTrials.gov lists 28 trials for Polycythemia or a narrower condition beneath it. AOP Orphan Pharmaceuticals AG has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
28 of the 28 trials are tagged with Polycythemia itself; the rest are tagged with a narrower condition beneath it.
When did Polycythemia trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 4 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 1 |
| 2016 | 1 |
| 2015 | 1 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 13 months across 13 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Polycythemia trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Phase 3 | 6 |
| Phase 4 | 4 |
| Not applicable | 4 |
| Observational | 8 |
| Expanded access | 1 |
How many Polycythemia trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 7 |
| Active, not recruiting | 2 |
| Completed | 10 |
| Terminated | 3 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Polycythemia trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AOP Orphan Pharmaceuticals AG | 2 |
| Eilean Therapeutics AU Pty Ltd | 1 |
| Geron Corporation | 1 |
| Incyte Corporation | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ruxolitinib IR | 2 |
| Acetazolamide Pill | 2 |
| Best Available Therapy | 2 |
| Delayed Cord Clamping (DCC) | 1 |
| Hyperpolarized Xe129 | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Polycythemia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Anaemia | 3 | 1 |
| Abdominal pain | 2 | 1 |
| Dyspnoea | 2 | 1 |
| Splenomegaly | 2 | 1 |
| Staphylococcal sepsis | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Polycythemia? (70)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females. | Blood advances | 2025 | Yes |
| Identification of Hepatic-like EPO as a Cause of Polycythemia. | The New England journal of medicine | 2025 | Yes |
| Effect of 100 mg of testosterone cypionate in trans men with erythrocytosis: a randomized controlled pilot study. | The journal of sexual medicine | 2025 | Yes |
| Carbon monoxide rebreathing method is a reliable test to evaluate the red cell mass in polycythaemia. | British journal of haematology | 2024 | Yes |
| Society for Maternal-Fetal Medicine Consult Series #72: Twin-twin transfusion syndrome and twin anemia-polycythemia sequence. | American journal of obstetrics and gynecology | 2024 | Yes |
Showing 5 of 70 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Erythrocytosis | 98427 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Erythrocytosis | 98427 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and sub-conditions in mesh.